Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

The Pathologist / Issues / 2019 / Jul / A Golden Ratio for Gut Disorders
Hematology Analytical science Hematology Microbiology and Immunology Point of care testing

A Golden Ratio for Gut Disorders

Could the permeability ratio be used to diagnose and monitor gut disorders less invasively than traditional colonoscopy?

By Luke Turner 07/19/2019 Quick Read (pre 2022) 1 min read

Share

Inflammatory bowel disease (IBD) is on the rise across the globe – especially in industrialized countries. By 2015, an estimated three million people in the US had received a diagnosis of either Crohn’s disease or ulcerative colitis, the two conditions collectively known as IBD (1). Characterized by chronic inflammation of the gastrointestinal tract, symptoms of the disease include stomach pain and swelling, bloody diarrhea, and weight loss. Typically, IBD is diagnosed and monitored through colonoscopy, which assesses structural damage to the intestine’s gut-blood barrier. But colonoscopy is invasive and requires anesthesia – and Marcin Ufnal of the Medical University of Warsaw might have found a better alternative.

Patients with IBD suffer from an impaired gut-blood barrier, which Ufnal and his team have harnessed to develop a novel test that compares the ratio of bacterial products in the patient’s blood and stool (2). “We initially wanted to use the concentration of gut bacterial products in the blood, but this didn’t work because there were significant inter-individual differences in bacterial composition, including geographic, dietary, and drug-related factors,” says Ufnal.

Credit: Marcin Ufnal.

In contrast, the blood-to-stool ratio of bacterial products isn’t affected by differences in the composition and metabolic activity of bacteria. “The permeability ratio (Pr) assesses the extent to which bacterial products have passed through the gut-blood barrier,” Ufnal explains. “A healthy individual will have a low Pr, whereas the ratio for an IBD patient will be higher.” Specifically, the Pr analyzes short-chain fatty acids in just 1 mL of blood and stool, measuring their concentration via liquid chromatography coupled with triple-quadrupole mass spectrometry.

Ufnal believes that the technique could also be used to diagnose other disorders that affect the function of the intestinal wall, such as celiac disease. In addition, it offers promise for the detection of heart failure, high blood pressure, and liver ailments, because they may all result in a leaky gut that affects the concentration of bacterial products in the blood.

Future efforts will be directed toward assessing which bacterial metabolites are most useful in terms of calculating Pr. “We are doing a lot of basic research to look for bacterial products that aren’t metabolized by the liver, because that can affect their concentration in systemic blood,” says Ufnal. Given that gut disorders can develop before any structural changes can be seen with traditional colonoscopy, this method of diagnosing and monitoring IBD offers hope that symptoms can be controlled at the earliest stage.

Newsletters

Receive the latest pathology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. JM Dahlhamer et al., “Prevalence of Inflammatory bowel disease among adults aged ≥18 Years - United States, 2015”, MMWR Morb Mortal Wkly Rep, 65, 1166 (2016). PMID: 27787492.
  2. K Jaworska et al., “Inflammatory bowel disease is associated with increased gut-to-blood penetration of short-chain fatty acids: A new, non-invasive marker of a functional intestinal lesion”, Exp Physiol, [Epub ahead of print] (2019). PMID: 31243807.

About the Author(s)

Luke Turner

While completing my undergraduate degree in Biology, I soon discovered that my passion and strength was for writing about science rather than working in the lab. My master’s degree in Science Communication allowed me to develop my science writing skills and I was lucky enough to come to Texere Publishing straight from University. Here I am given the opportunity to write about cutting edge research and engage with leading scientists, while also being part of a fantastic team!

More Articles by Luke Turner

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Related Content

Opening a Window into Brain Trauma
Analytical science
Opening a Window into Brain Trauma

January 18, 2024

4 min read

Raman spectroscopy shows promise as the first point-of-care diagnostic device for TBI

Could ≠ Should
Analytical science
Could ≠ Should

January 20, 2022

1 min read

The need to prevent the ordering of unnecessary tests

Diamonds Are a Diagnostician’s Best Friend
Analytical science
Diamonds Are a Diagnostician’s Best Friend

February 8, 2022

1 min read

A diagnostic sensor for rapid, cost-effective, and accurate detection of SARS-CoV-2

Hunting the Unknown
Analytical science
Hunting the Unknown

February 22, 2022

1 min read

When it comes to human health, we cannot ignore unknown molecules simply because they present analytical challenges

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.